Browse EX-10 agreements

Ex.10.1 TRANSITION AND BOARD SERVICE AGREEMENT June 29, 2026 Mr. Dhiren Fonseca At the address on file with the Company Dear Dhiren: This Transition and Board Service Agreement (the “Agreement”) confirms the agreement between you and Rent the Runway, Inc. (together with its subsidiaries and affiliates, the “Company”) describing the terms and conditions of the transition of your employment and role to a non-executive member of the Company’s Board of Directors (the “Board”). 1. Transition. Your title of Executive Chair of the Company, as set forth in the employment agreement by and between you and the Company, executed as of February 24, 2026 and effective as of October 28, 2025 (the “Employment Agreement”), will cease effective as of the earlier of (i) the Company’s appointment of a permanent Chief Executive Officer and (ii) January 31, 2027 (such earliest date to occur, the “Transition Date”). Effective July 1, 2026, your status shall be that of a Board member and not an employee or officer of the Company. During the period between July 1, 2026 and the Transition Date (the “Transitio

…

1 September 11, 2026 Paige Thomas Delivered via email: Pthomas2@renttherunway.com Dear Paige: On behalf of Rent the Runway, Inc. (the “Company”), we are pleased to offer you the position of Chief Executive Officer and President of the Company. This executive employment agreement (the “Agreement”) will be effective as of September 14, 2026 (the “Appointment Date” and the period from the Effective Date through your employment termination date, the “Term”) and sets forth the terms and conditions of your employment and position. As of the Effective Date, this Agreement will replace and supersede in its entirety your prior offer letter with the Company, dated as of May 29, 2026 (the “Prior Offer Letter”), other than as expressly set forth herein. APPOINTMENT DATE & LOCATION: Your appointment as Chief Executive Officer and President of the Company will be effective on the Appointment Date. You will continue to be based in our Brooklyn, NY headquarters. TITLE & DUTIES: During the Term, you will serve as Chief Executive Officer and President of the Company, reporting to the Board of Director

…

September 10, 2026

Karyopharm Therapeutics Inc.

85 Wells Avenue, Suite 210

Newton, MA 02459

Attention: Chief Financial Officer

Re:	Fee Agreement Pursuant to Forbearance Agreement

Ladies and Gentlemen:

Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), agreed, as a condition to the effectiveness of the Forbearance Agreement, dated as of the date hereof, by and among the Company and the Lenders (the “Forbearance Agreement”), to pay certain fees in cash or in the form of series A convertible preferred stock of the Company, par value $0.0001 per share, with an initial liquidation preference of one thousand dollars ($1,000) per share (the “Preferred Stock”), to each of the lenders (the “Lenders”) identified in Schedule I hereto, in an aggregate amount equal to $20,000,000.00, which shall be payable in cash or shares of Preferred Stock.

…

**FORBEARANCE AGREEMENT AND LIMITED WAIVER TO INDENTURES **

This Forbearance Agreement and Limited Waiver to Indentures, dated as of September 10, 2026 (this “Agreement”), is entered into by and among (i) Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”) and each of the undersigned subsidiaries of the Company that have executed and delivered counterpart signature pages to this Agreement (collectively, with the Company, the “Company Parties”); (ii) the undersigned parties that have executed and delivered counterpart signature pages to this Agreement in their respective capacities as Lenders constituting Requisite Lenders under and as defined in the Term Loan Credit Agreement (as defined below) (together with any other Lender that executes a joinder to this Agreement, the “Consenting Term Lenders”); (iii) the undersigned parties that have executed and delivered counterpart signature pages to this Agreement in their respective capacities as persons holding beneficial ownership interests in the Company’s 9.00% Convertible Senior Notes due 2028 (the “*2028 Note

…

---

Exhibit 10.1

Date:	September 11, 2026
To:	NewHold Investment Corp III, a Cayman Islands exempted company with limited liability (“NewHold”), and newcleo plc, a public limited company under the laws of England and Wales (“PubCo”).

…

***SEPARATION AGREEMENT AND RELEASE ***

This SEPARATION AGREEMENT AND RELEASE (the “Agreement”) is entered into by and between Park Hotels & Resorts Inc. (the “Company”) and Thomas C. Morey (“Executive”) (collectively, the “Parties”), and shall be effective as set forth in Section 6(a).

WHEREAS, Executive served as Executive Vice President and Chief Investment Officer as well as General Counsel of the Company;

WHEREAS, Executive’s employment with the Company terminated without Cause on September 8, 2026 (the “Separation Date”);

WHEREAS, Executive is a participant in the Park Hotels & Resorts Inc. Executive Severance Plan (the “Severance Plan”);

**WHEREAS, **the Parties previously entered an Indemnification Agreement effective as of December 20, 2016 (“Indemnification Agreement”); and

WHEREAS, the Company and Executive desire to enter into this Agreement to set out the terms and conditions of Executive’s termination of employment with the Company in accordance with the terms and conditions of the Severance Plan.

…

** **

Exhibit 10.3

** **

REGISTRATION RIGHTS AGREEMENT

** **

This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], 2026 (the “Closing Date”), by and among Gravitics Holdings, Inc. (f/k/a Non-Invasive Monitoring Systems, Inc.), a Florida corporation (the “Company”), and the undersigned parties listed under Holders on the signature page hereto (each such party, together with any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2 of this Agreement, a “Holder” and collectively, the “Holders”).

RECITALS

…

**Exhibit 10.11 **

**LICENSE AGREEMENT **

This LICENSE AGREEMENT****** (this “Agreement”) is entered into as of April 23, 2025 (the “Effective Date**”), by and between Caldera Therapeutics, Inc., a Delaware corporation with a business address at 300 Technology Square, 8th Floor, Cambridge, MA 02139, U.S.A. (“Licensee”), and** QYUNS**** THERAPEUTICS CO., LTD., a *Chinese company with an address at No.907 Yaocheng Avenue, Taizhou, Jiangsu, China (“Qyuns”). Qyuns and Licensee are referred to in this Agreement individually as a “Party” and collectively as the “Parties.*”

**BACKGROUND **

WHEREAS, Qyuns is willing to grant to Licensee, and Licensee is willing to accept, under certain intellectual property owned or controlled by Qyuns, an exclusive, worldwide license to develop and commercialize the Licensed Products (as defined herein) all on the terms and conditions herein.

…

---

[Execution Version]

CONFIDENTIAL

PUT OPTION AGREEMENT

by and between

SURGEPAYS, INC., as Holder

and

EMERALD SHOALS TARGETED OPPORTUNITIES FUND LP, as Fund

Acknowledged by GPOX

Dated as of September 7, 2026

1

PUT OPTION AGREEMENT (this “Agreement”) is made as of September 7, 2026, by and between SurgePays, Inc., a Nevada corporation (“Holder”), and Emerald Shoals Targeted Opportunities Fund LP, an Ohio limited partnership (“Fund”), and is acknowledged by GPO Plus, Inc., a Nevada corporation (“GPOX”), solely as expressly provided herein. This Agreement is delivered in connection with the Asset Purchase Agreement dated as of September 7, 2026 among Holder, GPOX and ClearLine Apps, LLC (the “Purchase Agreement”). Under the Purchase Agreement, Holder is receiving 25,000,000 shares of GPOX Series D Convertible Preferred Stock solely in satisfaction of the $27,500,000 ClearLine Purchase Price. Fund and/or its affiliates are, as of the date of this Agreement, the largest holder(s) of the common stock of GPOX and, on that ba

…

[Execution Copy]

---

CONFIDENTIAL

**ASSET PURCHASE AGREEMENT **

by and among

**GPO PLUS, INC., as Purchaser **

**CLEARLINE APPS, LLC, as Acquisition Subsidiary **

and

**SURGEPAYS, INC., as Seller **

Dated as of September 7, 2026** **

1

ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of September 7, 2026, by and among GPO Plus, Inc., a Nevada corporation (“GPOX” or “Purchaser”), ClearLine Apps, LLC, a Nevada limited liability company wholly owned by GPOX (“Acquisition Subsidiary”), and SurgePays, Inc., a Nevada corporation (“SURG” or “Seller”).

The parties intend a straightforward asset acquisition between friendly companies. Seller is selling only the Purchased Assets expressly described in this Agreement and the Schedules. Seller is retaining its existing SurgePays-branded wireless and MVNO business and the parties intend that the transaction not disrupt that retained business.

**ARTICLE I **

**PURCHASE AND SALE **

…

INDEMNIFICATION AGREEMENT

This Indemnification Agreement (“Agreement”), dated as of [DATE], is by and between LightPath Technologies, Inc., a Delaware corporation (the “Company”) and [DIRECTOR] (the “Indemnitee”).

WHEREAS, the Company expects Indemnitee to join the Company as a director;

WHEREAS, both the Company and Indemnitee recognize the increased risk of litigation and other claims being asserted against directors and officers of public companies;

WHEREAS, the board of directors of the Company (the “Board”) has determined that enhancing the ability of the Company to retain and attract as directors and officers the most capable persons is in the best interests of the Company and that the Company therefore should seek to assure such persons that indemnification and insurance coverage is available; and

…

** **

e**xhibit 10.16**

** **

License Agreement

This License Agreement (this “Agreement”), dated as of July 14, 2025 (the “Effective Date”), is by and between PrimeGen Biotech LLC, a Delaware limited liability company, having its principal place of business at 2917 S. Daimler Street, Santa Ana, CA 92705 (“Licensor”), and PrimeGen US, Inc., a Delaware corporation, having its principal place of business at 2917 S. Daimler Street, Santa Ana, CA 92705 (“Licensee”) (collectively, the “Parties,” or each, individually, a “Party”).

RECITALS

WHEREAS, substantially simultaneously with the execution of this Agreement, Licensee and Licensor are entering into that certain Patent and Technology Assignment Agreement, dated as of even date herewith (the “Assignment Agreement”);

WHEREAS, Licensee is a biotechnology company engaged in the business of developing and commercializing novel stem cell and related therapies; and

…